About: http://data.cimple.eu/news-article/a65714ff65a00d8d3921d08e05f212e8dac9d0373dc5eff64fb025cf     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • Canada's Medicago and British pharmaceutical giant GlaxoSmithKline (GSK) announced Thursday the launch of phase 2 and 3 clinical trials on a Covid-19 vaccine, one of a series of candidates being developed worldwide. Final phase 3 trials of the plant-derived vaccine candidate will begin by year's end and will be tested on 30,000 volunteers in North America, Latin America and Europe, according to a joint statement. Phase 2 trials will be conducted in multiple locations across Canada and, upon government approval, in the United States. A global scramble has been underway to develop and test vaccines against the coronavirus, which has sickened tens of millons of people worldwide and deeply wounded the global economy. On Tuesday, Medicago reported that its vaccine candidate resulted in "100 percent" protection in 180 healthy people who participated in its phase 1 clinical trials. The company's executive vice president of scientific and medical affairs Nathalie Landry said those results were "very encouraging and fully support further clinical evaluation." GSK's chief medical officer Thomas Breuer said GSK was "confident (about) delivering an efficacious vaccine with an acceptable safety profile in collaboration with Medicago." "This is the first of several GSK Covid-19 vaccine candidate collaborations to start Phase 2/3 clinical testing and an important step forward in our contribution to the global fight against the pandemic," he said. The studies will look to confirm that the formulation along with dosing -- given 21 days apart -- is safe and triggers the body's immune response in healthy adults aged 18-64 years and in elderly subjects aged 65 and over. The Canadian government in October pledged up to Can$173 million (US$132 million) to help develop the vaccine, and placed a tentative order for 76 million doses. jl/amc/jm
schema:headline
  • Medicago and GSK to begin final Covid-19 vaccine trials
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
http://data.cimple...tology#hasEmotion
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 3 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software